NLS Pharmaceutics AG (NLSP) — Financial Flexibility Index

Latest as of September 2025: -1.43x

NLS Pharmaceutics AG (NLSP) has a Financial Flexibility Index of -1.43x as of September 2025. Free cash flow of $-2.07 Million (operating CF $-2.07 Million minus capex $0.00) represents -1% of total liabilities ($1.46 Million). Check NLS Pharmaceutics AG (NLSP) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-1.43x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-2.07 Million
Operating CF − Capex

Total Liabilities

$1.46 Million
USD

Capital Expenditures

$0.00
USD

NLS Pharmaceutics AG Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for NLS Pharmaceutics AG across 8 annual periods. For the full cash flow conversion analysis, see NLS Pharmaceutics AG cash conversion from operations.

Annual Financial Flexibility Index for NLS Pharmaceutics AG (2017–2024)

Year-by-year free cash flow to debt coverage for NLS Pharmaceutics AG. Explore NLSP cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -5.16x $-4.26 Million $-4.27 Million $826.76K ▼ -468.8%
2023 -0.91x $-9.68 Million $-9.68 Million $10.68 Million ▲ +60.8%
2022 -2.31x $-13.88 Million $-13.88 Million $6.00 Million ▲ +18.8%
2021 -2.85x $-14.90 Million $-14.94 Million $5.22 Million ▼ -3887.3%
2020 -0.07x $-729.38K $-729.39K $10.20 Million ▼ -226.5%
2019 -0.02x $-150.45K $-190.01K $6.87 Million ▲ +92.7%
2018 -0.30x $-2.69 Million $-2.73 Million $8.96 Million ▲ +44.6%
2017 -0.54x $-5.43 Million $-5.43 Million $10.01 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities